Novogen is an oncology-focused biotechnology company, based in Sydney, Australia. We are listed on the Australian Securities Exchange (NRT) and on NASDAQ (NVGN). Our primary business is to discover and develop new therapies for a range of different cancers.

Working with Novogen

Our pipeline currently encompasses three first-in-class new chemical entities, which have been designated Cantrixil, Anisina, and Trilexium. Cantrixil is due to enter clinical trials in the second half of 2016, with a lead indication of ovarian cancer, while Anisina and Trilexium are continuing preclinical development.

We operate in a lean, virtual organisation, with staff based in Sydney, Melbourne, and the United States. More than half of our team are PhD graduates, and the inventors of our key technologies remain part of the company. The management team is overseen by a Board of Directors, with international membership encompassing senior leaders from life sciences, academia, and financial services.

The company is well-funded to pursue its lead programs into the clinic, with approximately AU$ 40M of cash reserves and access to the Australian Government’s R&D Tax Rebate scheme. On current cash burn projections, the company is funded to mid-2018.

Novogen strives to build a corporate culture that is entrepreneurial in nature, non-hierarchical in structure, global in outlook, and which is focused above all on providing benefit to patients.

Novogen is an equal-opportunity employer, committed to working with the very best people, regardless of age, gender, race, sexuality or other considerations.

Our company anticipates an exciting future, and we welcome expressions of interest from suitably-qualified candidates to join our team. Please share a brief curriculum vitae to and we will respond at the earliest opportunity.